Prostate Cancer

News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.

Research in the March 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network examined data from the Ontario Cancer Registry from September 25, 2016 through September 26, 2020, to determine the impact of the COVID-19 pandemic on the number of new cancer cases detected.
News | Coronavirus (COVID-19)
New Research in JNCCN Measures Drop in Cancer Detection Due to the COVID-19 Pandemic

April 6, 2022 — Research in the March 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network examined ...

Time April 06, 2022
arrow
On Friday, April 1 at 2 p.m., the Milton and Caroll Petrie Department of Urology at Mount Sinai will host a ribbon cutting ceremony in Wagner Houses’ Community Plaza Ground, 451 East 120th Street, to celebrate the launch of the Mount Sinai Robert F. Smith Mobile Prostate Cancer Screening Unit.
News | Prostate Cancer
Mount Sinai Health System Launches First-Ever Mobile Prostate Cancer Screening Unit in New York City

April 6, 2022 — On Friday, April 1 at 2 p.m., the Milton and Caroll Petrie Department of Urology at Mount Sinai will ...

Time April 06, 2022
arrow
The American College of Radiology (ACR) has selected 22 teams as the first cohort of the ACR Learning Network, a new initiative to improve diagnostic imaging through a learning health system approach.
News | Radiology Education
New ACR Initiative Harnesses Learning Health System Approach to Improve Diagnostic Imaging

April 5, 2022 — The American College of Radiology (ACR) has selected 22 teams as the first cohort of the ACR Learning ...

Time April 05, 2022
arrow
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports Advanced Accelerator Applications, a Novartis company, as a long-term supplier for the medical radioisotope component of the newly U.S. Food and Drug Administration (FDA) approved radiotherapeutic, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treat
News | Prostate Cancer
ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer

March 28, 2022 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports ...

Time March 28, 2022
arrow
With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical therapy to treat metastatic castration-resistant prostate cancer (mCRPC)—the Society of Nuclear Medicine and Molecular Imaging (SNMMI) celebrates one of the greatest success stories in nuclear medicine history.
News | Prostate Cancer
SNMMI Applauds FDA Approval of New Metastatic Prostate Cancer Treatment

March 23, 2022 — With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical ...

Time March 23, 2022
arrow
A new study from Keck Medicine of USC finds that the incidence rate of metastatic prostate cancer has significantly increased for men 45 and older and coincides with recommendations against routine prostate cancer screenings.
News | Prostate Cancer
Metastatic Prostate Cancer on the Rise Since Decrease in Cancer Screenings

March 23, 2022 — A new study from Keck Medicine of USC finds that the incidence rate of metastatic prostate cancer has ...

Time March 23, 2022
arrow
Convergent will use NorthStar’s Ac-225 to radiolabel its lead asset, CONV01-α, a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody, currently being investigated as a potential ground-breaking treatment for prostate cancer.
News | Prostate Cancer
NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

March 11, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time March 11, 2022
arrow
18F-rhPSMA-7.3 PET Photo courtesy of Blue Earth Diagnostics. General use: This 18F-rhPSMA-7.3 PET image shows prostate cancer spread beyond the prostate region. Technical use: This 18F-rhPSMA-7.3 PET image shows detection of recurrent prostate cancer in several retroperitoneal lymph nodes, as indicated by the green arrows.
News | Prostate Cancer
Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of 18F-rhPSMA-7.3

February 18, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time February 18, 2022
arrow
Benign Prostatic Hyperplasia (BPH) or prostate adenoma seen on MRI examination
News | Prostate Cancer
MRI-guided Radiotherapy Appears to Lead to Fewer Side Effects from Treatment for Prostate Cancer

February 17, 2022 — An interim analysis of an ongoing Phase III study from UCLA Jonsson Comprehensive Cancer Center ...

Time February 17, 2022
arrow
The American College of Radiology (ACR) reports that several states are considering breast, colon and lung cancer screening measures.
News | Radiology Imaging
States Advance Cancer Screening, Prior Authorization and Scope of Practice Legislation

The American College of Radiology (ACR) reports that several states are considering breast, colon and lung cancer ...

Time February 14, 2022
arrow
The American Society for Radiation Oncology (ASTRO) issued the following statement from ASTRO Board of Directors Chair Laura A. Dawson, M.D., FASTRO, in response to today's announcement that President Joe Biden will reignite the Cancer Moonshot initiative to accelerate the rate of progress in the nation's fight against cancer
News | Radiation Oncology
Radiation Oncologists Applaud Biden-Harris Administration's Renewed Commitment to Cancer Moonshot

February 3, 2022 — The American Society for Radiation Oncology (ASTRO) issued the following statement from ASTRO Board ...

Time February 03, 2022
arrow
Urgent and immediate action must be taken to ensure more effective and equitable implementation of cancer screening, according to a report released today by the President's Cancer Panel.
News | Radiology Imaging
President's Cancer Panel Calls for Urgent Action to Address Gaps in Cancer Screening Uptake

February 2, 2022 — Urgent and immediate action must be taken to ensure more effective and equitable implementation of ...

Time February 02, 2022
arrow
PET disease extent in EAU BCR low-risk patients, EAU BCR high-risk patients, and BCP patients (A) and predictors of PET M1 disease (B). OR = odds ratio. Image courtesy of Justin Ferdinandus, Wolfgang P. Fendler, Andrea Farolfi, et al.
News | Prostate Cancer
PSMA PET Validates EAU Classification System to Determine Risk of Prostate Cancer Recurrence

January 24, 2022 — New research has confirmed the accuracy of the novel European Association of Urology (EAU) risk ...

Time January 24, 2022
arrow
For the first time, researchers led by a team from the UCLA Jonsson Comprehensive Cancer Center used prostate cancer patients’ DNA to create a model that appears to predict who will have side effects from radiation.   
News | Prostate Cancer
Genetics Predicts Toxic Side Effects to Prostate Cancer Radiotherapy

January 19, 2022 — For the first time, researchers led by a team from the UCLA Jonsson Comprehensive Cancer Center used ...

Time January 19, 2022
arrow
A versatile light-sheet microscope developed at the University of Washington can provide surgeons with real-time pathology data to guide cancer-removal surgeries and can also non-destructively examine tumor biopsies in 3-D. Image courtesy of Mark Stone/University of Washington
News | Prostate Cancer
3-D Imaging Method May Help Doctors Better Determine Prostate Cancer Aggressiveness

December 10, 2021 — Prostate cancer is the most common cancer for men and, for men in the United States, it's the second ...

Time December 10, 2021
arrow
A new Harvey L. Neiman Health Policy Institute study of nearly 800,000 men found that between 2011 and 2017 black patients were 24% less likely than white patients to have a prostate MRI after receiving an elevated (prostate-specific antigen) PSA score
News | Prostate Cancer
Black Patients 24% Less Likely than White Patients to Have a Prostate MRI After Receiving an Elevated PSA Score

November 16, 2021 — A new Harvey L. Neiman Health Policy Institute study of nearly 800,000 men found that between 2011 ...

Time November 16, 2021
arrow
Videos | Radiation Oncology
VIDEO: MRI-Linac and PSMA PET Imaging Technologies Aids Therapy at GenesisCare

Walter Curran, Jr. M.D., FACR, FASCO, GenesisCare global chief medical officer, discusses three technologies that are ...

Time November 16, 2021
arrow
Veracyte Inc. announced that new data being presented at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting suggest the company’s Decipher Prostate genomic classifier identifies patients with clinically high-risk prostate cancer who may require treatment intensification beyond standard-of-care therapy
News | Prostate Cancer
Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer

November 11, 2021 — Veracyte Inc. announced that new data being presented at the American Society for Radiation Oncology ...

Time November 11, 2021
arrow
An individual patient data (IPD) meta-analysis of randomized, controlled clinical trials provides strong evidence for the addition of androgen deprivation therapy (ADT) to definitive radiotherapy (RT) for the treatment of prostate cancer, with the projection that adding ADT to the treatment of 10-15 men would prevent the development of distant metastasis in one man.
News | Prostate Cancer
International Meta-analysis Quantifies Impact of Three Prostate Cancer Therapy Intensification Strategies

October 28, 2021 — An individual patient data (IPD) meta-analysis of randomized, controlled clinical trials provides ...

Time October 28, 2021
arrow
A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy.
News | Prostate Cancer
Genetic Biomarker Test Predicts Recurrence and Survival Outcomes for Men with High-risk Prostate Cancer

October 25, 2021 — A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk ...

Time October 25, 2021
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now